Ovid Therapeutics shares are trading higher after the company, and Takeda Pharmaceutical, announced the Phase 2 ELEKTRA study of Soticlestat met its primary endpoint, reducing seizure frequency in children with Dravet Syndrome or Lennox-Gastaut Syndrome.